Ottawa, June 6, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, applauds the Quebec government on the launch of its rare disease strategy.
“Patients suffering from rare diseases face unique challenges, and we congratulate the Quebec government for being the first in Canada to launch a strategy to help address their needs,” said Pamela Fralick, President of Innovative Medicines Canada. “This is a critical first step towards ensuring the approximately 700,000 Quebec residents suffering from rare diseases get timely access to health care services, diagnoses, and treatments.”
IMC actively participated in the consultations leading up to the launch of the strategy and recognizes Quebec’s leadership in adopting a definition for rare diseases that is aligned with international standards. The association looks forward to continuing its work with the Quebec government in creating an action plan that increases patient access to new medicines and treatments for those suffering from rare diseases.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information:
Director, Media Relations & Content